Literature DB >> 2857774

Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance.

D R Bell, J H Gerlach, N Kartner, R N Buick, V Ling.   

Abstract

A multidrug resistance phenotype is frequently observed in animal and human cell lines selected for in vitro resistance to a single chemotherapeutic agent. Overexpression of a highly conserved cell-surface glycoprotein (P-glycoprotein) is consistently associated with this phenotype in these mutant lines. A monoclonal antibody against P-glycoprotein was used to examine tumor samples from five patients with advanced ovarian cancer for evidence of P-glycoprotein overexpression. High levels of P-glycoprotein were detected in samples from two patients suggesting that a multidrug resistance mutation may also occur in ovarian cancer. This finding has broad implications for the understanding of nonresponse to chemotherapy in a variety of human neoplasms, and may provide a rational explanation for failure of chemotherapy in treatment of advanced ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2857774     DOI: 10.1200/JCO.1985.3.3.311

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  83 in total

Review 1.  Overcoming drug resistance in ovarian carcinoma.

Authors:  P M Fracasso
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

2.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.

Authors:  M Kavallaris; D Y Kuo; C A Burkhart; D L Regl; M D Norris; M Haber; S B Horwitz
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 3.  Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.

Authors:  Xiaowei Dong; Russell J Mumper
Journal:  Nanomedicine (Lond)       Date:  2010-06       Impact factor: 5.307

Review 4.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Overexpression and amplification of five genes in a multidrug-resistant Chinese hamster ovary cell line.

Authors:  A M Van der Bliek; T Van der Velde-Koerts; V Ling; P Borst
Journal:  Mol Cell Biol       Date:  1986-05       Impact factor: 4.272

6.  Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies.

Authors:  H Hamada; T Tsuruo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

Review 7.  Quantitative genetic analysis of tumor progression.

Authors:  V Ling; A F Chambers; J F Harris; R P Hill
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

8.  Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.

Authors:  Xiao-Han Tang; Suo Deng; Meng Li; Mei-Song Lu
Journal:  Tumour Biol       Date:  2015-11-16

Review 9.  Transient receptor potential channel C5 in cancer chemoresistance.

Authors:  Dong-xu He; Xin Ma
Journal:  Acta Pharmacol Sin       Date:  2015-12-14       Impact factor: 6.150

10.  Prediction of the resistance of human tumors to adriamycin by chemosensitivity tests and DNA analysis of the multidrug resistance gene.

Authors:  R Kim; T Saeki; S Takagami; Y Kirihara; K Jinushi; M Nishiyama; M Niimoto; T Hattori; K Okada
Journal:  Jpn J Surg       Date:  1990-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.